Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Cresco Labs Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Cresco Labs şirketinin toplam hissedar öz sermayesi $374.5M ve toplam borcu $416.3M olup, bu da borç-öz sermaye oranını 111.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $1.4B ve $983.5M dir. Cresco Labs 'in FAVÖK'ü $110.3M faiz karşılama oranı 2 dur. Şirketin $112.3M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

111.2%

Borç/özkaynak oranı

US$416.30m

Borç

Faiz karşılama oranı	2x
Nakit	US$112.30m
Eşitlik	US$374.51m
Toplam yükümlülükler	US$983.54m
Toplam varlıklar	US$1.36b

Son finansal sağlık güncellemeleri

Recent updates

Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Aug 11

Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?

Jul 17

Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden

Jun 19

Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jun 19

Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

Mar 16

Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%

Mar 03

Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt

Jan 26

Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)

Jan 04

Is Cresco Labs (CSE:CL) Using Too Much Debt?

Sep 22

Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 33%

Aug 11

Cresco Labs (CSE:CL) Has A Somewhat Strained Balance Sheet

Jan 25

Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 24%?

Dec 13

We Think Cresco Labs (CSE:CL) Is Taking Some Risk With Its Debt

Aug 22

Estimating The Intrinsic Value Of Cresco Labs Inc. (CSE:CL)

May 23

Cresco Labs Inc. (CSE:CL) Analysts Are Way More Bearish Than They Used To Be

Mar 24

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CL 'nin kısa vadeli varlıkları ( $273.4M ) kısa vadeli yükümlülüklerini ( $136.9M ) aşıyor.

Uzun Vadeli Yükümlülükler: CL 'un kısa vadeli varlıkları ( $273.4M ) uzun vadeli yükümlülüklerini ( $846.7M ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CL 'nin net borç/öz sermaye oranı ( 81.2% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: CL şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 111.2% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: Kârsız olan CL mevcut pozitif serbest nakit akışı seviyesini koruduğu takdirde 3 yıldan fazla yetecek nakit pistine sahip olacaktır.

Tahmini Nakit Akışı: CL kârlı değildir ancak serbest nakit akışının pozitif olması ve yılda % 21.6 oranında büyümesi nedeniyle 3 yıldan fazla bir süre yetecek nakit akışına sahiptir.

Cresco Labs Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden

Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt

Is Cresco Labs (CSE:CL) Using Too Much Debt?

Cresco Labs (CSE:CL) Has A Somewhat Strained Balance Sheet

We Think Cresco Labs (CSE:CL) Is Taking Some Risk With Its Debt

Recent updates

Cresco Labs Inc. Announces Resignation of Tarik Brooks as Board of Directors

Cresco Labs Inc. Announces CFO Changes

New minor risk - Profitability

No longer forecast to breakeven

Co-Founder & Independent Director recently sold CA$110k worth of stock

Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.12 loss in 2Q 2023)

Cresco Labs Inc. to Report Q2, 2024 Results on Aug 08, 2024

Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?

Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden

Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Co-Founder & Independent Director recently sold CA$236k worth of stock

New minor risk - Shareholder dilution

Co-Founder & Independent Director recently sold CA$124k worth of stock

Co-Founder & Independent Director recently sold CA$124k worth of stock

Co-Founder & Independent Director recently sold CA$364k worth of stock

First quarter 2024 earnings released: US$0.015 loss per share (vs US$0.085 loss in 1Q 2023)

Cresco Labs Inc. (CNSX:CL) acquired Two medical dispensaries in Pennsylvania of Keystone Integrated Care, LLC for $9.8 million.

Consensus EPS estimates upgraded to US$0.055 loss

Cresco Labs Inc. to Report Q1, 2024 Results on May 15, 2024

Cresco Labs Inc., Annual General Meeting, Jun 10, 2024

Forecast to breakeven in 2026

Consensus EPS estimates upgraded to US$0.059 loss

Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

New minor risk - Profitability

Full year 2023 earnings released: US$0.53 loss per share (vs US$0.71 loss in FY 2022)

Forecast to breakeven in 2025

New minor risk - Shareholder dilution

Chief Financial Officer exercised options to buy CA$150k worth of stock.

Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%

Cresco Labs Inc. to Report Q4, 2023 Results on Mar 13, 2024

Cresco Labs Inc. Promotes Greg Butler to the Position of President

Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt

New minor risk - Shareholder dilution

Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)

New minor risk - Shareholder dilution

Consensus EPS estimates fall by 91%, revenue upgraded

Third quarter 2023 earnings released: US$0.34 loss per share (vs US$0.033 loss in 3Q 2022)

Cresco Labs Inc. to Report Q3, 2023 Results on Nov 15, 2023

New major risk - Share price stability

Cresco Labs Inc. completed the acquisition of Sole Licensed Arizona Operation of Cresco Labs Inc.

No longer forecast to breakeven

Is Cresco Labs (CSE:CL) Using Too Much Debt?

New minor risk - Shareholder dilution

Consensus EPS estimates fall by 42%

Chief Financial Officer recently bought CA$149k worth of stock

Price target decreased by 8.4% to CA$4.80

Cresco Labs Inc. Provides Revenue Guidance for the Second Half of 2023

Second quarter 2023 earnings released: US$0.14 loss per share (vs US$0.046 loss in 2Q 2022)

Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 33%

Cresco Labs Inc. to Report Q2, 2023 Results on Aug 16, 2023

Insufficient new directors

Consensus EPS estimates fall by 15%

Price target decreased by 36% to CA$3.82

First quarter 2023 earnings released: US$0.092 loss per share (vs US$0.094 loss in 1Q 2022)

Cresco Labs Inc. to Report Q1, 2023 Results on May 24, 2023

Consensus EPS estimates fall by 40%

Insider recently sold CA$157k worth of stock

Consensus EPS estimates fall by 109%

Full year 2022 earnings released: US$0.71 loss per share (vs US$1.22 loss in FY 2021)

Cresco Labs (CSE:CL) Has A Somewhat Strained Balance Sheet

Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 24%?

Now 22% undervalued after recent price drop

Co-Founder & Independent Director recently sold CA$1.7m worth of stock

Forecast breakeven date moved forward to 2023

Forecast breakeven date pushed back to 2024

Now 20% undervalued after recent price drop

Third quarter 2022 earnings released: US$0.011 loss per share (vs US$1.00 loss in 3Q 2021)

Combs Enterprises signed a definitive agreements to acquire Certain New York, Illinois, and Massachusetts assets of Cresco Labs Inc. and Columbia Care Inc. for approximately $190 million.

Price target decreased to CA$10.10